Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist.
DuP 532 (2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)bip hen yl- 4-yl)methyl]imidazole-5-carboxylic acid) inhibited the specific binding of [125I]angiotensin II (AII) for the subtype receptor AT1 in rat adrenal cortical membranes with an IC50 of 3.1 X 10(-9) M, but not the [125I]AII binding for the subtype AT2 sites in rat adrenal medulla tissues. It inhibited the contractile response to AII selectively and noncompetitively in the isolated rabbit aorta with a KB value of 1.1 X 10(-10) M. The selective AII antagonism was confirmed in the guinea pig ileum and the pithed rat. In conscious rats, DuP 532 inhibited the AII-induced pressor effect, aldosterone secretion, and water drinking induced by AII. In conscious renal hypertensive rats, DuP 532 decreased blood pressure with i.v. and p.o. ED30 of 0.02 and 0.21 mg/kg, respectively. The antihypertensive effect of DuP 532 at 0.3 to 3 mg/kg p.o. lasted for at least 24 hr. In conscious spontaneously hypertensive rats, DuP 532 given i.v. or p.o. at 0.3 to 3 mg/kg reduced blood pressure dose-dependently. DuP 532, at doses up to 100 mg/kg i.v., did not cause a pressor response in conscious normotensive rats, suggesting lack of agonism. DuP 532 exerted selective AII antagonism in conscious dogs. In conscious furosemide-treated dogs, DuP 532 given either at 0.3 and 1 mg/kg i.v. or at 1 to 10 mg/kg p.o. decreased blood pressure. As the AT1 receptors are responsible for AII-induced vasoconstriction, aldosterone secretion, and water drinking, our study indicates that DuP 532 is a potent, orally active, selective, and noncompetitive AT1 receptor antagonist and antihypertensive agent.
Wong
P C
PC
Du Pont Merck Pharmaceutical Company, Wilmington, Delaware.
Hart
S D
SD
Chiu
A T
AT
Herblin
W F
WF
Carini
D J
DJ
Smith
R D
RD
Wexler
R R
RR
Timmermans
P B
PB
D000302:Adrenal Cortex / Q000378:metabolism; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000378:metabolism; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000502:physiology; D001345:Autoradiography; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006977:Hypertension, Renal / Q000188:drug therapy; D007082:Ileum / Q000187:drug effects / Q000502:physiology; D007093:Imidazoles / Q000378:metabolism / Q000494:pharmacology*; D066298:In Vitro Techniques; D007700:Kinetics; D008099:Liver / Q000033:anatomy & histology / Q000378:metabolism; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D011918:Rats, Inbred SHR; D011919:Rats, Inbred Strains; D013777:Tetrazoles / Q000378:metabolism / Q000494:pharmacology*; D005466:Fluorocarbons
D000804:Angiotensin II; D057911:Angiotensin Receptor Antagonists; D007093:Imidazoles; D013777:Tetrazoles; C069045:DuP 532; D005466:Fluorocarbons